Molecular mechanisms of FSP1-regulated ferroptosis and therapeutic implications in various cancers

Cancer cells are skilled survivors. They acquire mutations, hijack metabolic pathways, and build redundant escape routes so that treatments aimed at killing them often fail to land. One of the more intriguing escape routes that researchers are now mapping in detail involves a pathway called ferroptosis -- a specific form of cell death that many cancers actively shut down. At the center of that shutdown is a protein called FSP1, ferroptosis suppressor protein 1.

A 2025 review published in Cell Death & Disease (https://pubmed.ncbi.nlm.nih.gov/42337422/) pulls together the current mechanistic picture and asks what it means for cancer therapy. The answer is nuanced -- and worth understanding if you follow oncology research, are navigating a cancer diagnosis yourself, or simply want to understand how cell biology is shaping the treatments researchers are working on now.

This post explains the core science plainly, names what is established versus still experimental, and is honest about how far the research is from your clinic or hospital room.

What ferroptosis actually is

Ferroptosis is not apoptosis. That distinction matters because most oncology drugs -- and most of what the public knows about cancer cell death -- centers on apoptosis, the orderly, caspase-driven self-destruction program that chemotherapy and targeted therapy try to trigger.

Ferroptosis is different in mechanism and in feel. It was formally described and named in 2012 (https://pubmed.ncbi.nlm.nih.gov/22632970/) and works through iron-dependent lipid peroxidation. In plain language: iron inside the cell catalyzes a chain reaction that oxidizes the fatty acids embedded in cell membranes. When enough of those fats are damaged, the membrane fails and the cell dies. There is no caspase cascade. There is no neat, apoptotic corpse. The cell essentially ruptures under oxidative pressure.

Why does this matter clinically? Because some cancer cells -- particularly those that have become resistant to apoptosis-based killing -- remain sensitive to ferroptosis. The cell that has learned to block its own apoptosis machinery may not have learned to block membrane lipid oxidation. That is the therapeutic opening researchers are working to exploit (https://pubmed.ncbi.nlm.nih.gov/28985560/).

The two main checkpoints that keep ferroptosis from happening inside healthy cells are the GPX4 pathway (which uses glutathione to neutralize lipid peroxides) and the FSP1-CoQ10 pathway. The second one is what this post is about.

The FSP1-CoQ10 axis -- the cell's second line of defense

For most of the early ferroptosis literature, researchers focused almost entirely on GPX4 (glutathione peroxidase 4). GPX4 uses glutathione to detoxify lipid hydroperoxides before they can propagate membrane damage. Blocking GPX4 -- or depleting glutathione -- was considered the primary way to push a cell into ferroptosis.

Then, in 2019, two independent research groups published back-to-back papers in Nature (https://pubmed.ncbi.nlm.nih.gov/31634900/, https://pubmed.ncbi.nlm.nih.gov/31634899/) showing that cells have a completely separate system that can suppress ferroptosis even when GPX4 is gone. That system is FSP1.

Here is how it works. FSP1 is an oxidoreductase -- an enzyme that transfers electrons. It sits at the plasma membrane and uses NADH to regenerate coenzyme Q10 (CoQ10) into its reduced form, ubiquinol. Ubiquinol then acts as a lipid-soluble antioxidant, intercepting lipid peroxyl radicals at the membrane surface before they can oxidize neighboring fatty acids and spread membrane damage.

The practical consequence is significant. A cancer cell that upregulates FSP1 can resist ferroptosis-inducing treatments even when GPX4 is blocked. This is almost certainly one mechanism behind resistance to RSL3, erastin, and other ferroptosis-inducing compounds that researchers have been studying. The cell simply routes around the GPX4 blockade using FSP1.

Because FSP1 depends on NADH as a cofactor, it also sits downstream of NAD+ metabolism -- which is an area of active interest in longevity and cellular health research more broadly. We cover the role of NAD+ biology in our post on NAD+ therapy and cellular rejuvenation.

How cancer cells exploit FSP1

The 2025 review (https://pubmed.ncbi.nlm.nih.gov/42337422/) catalogs the cancer types in which FSP1 overexpression has been documented and what that overexpression appears to do. A few patterns are worth highlighting.

Lung cancer. Non-small cell lung cancer lines with high FSP1 expression show substantially reduced sensitivity to ferroptosis induction compared with low-FSP1 lines. The FSP1-CoQ10 axis appears particularly active in cancers that arise in tissues with high baseline oxidative stress, where cells may have already upregulated antioxidant machinery before malignant transformation.

Pancreatic cancer. Pancreatic ductal adenocarcinoma is notoriously resistant to most therapies. Evidence suggests high FSP1 activity contributes to that resistance, in part because the tumor microenvironment in pancreatic cancer is iron-rich -- which would ordinarily favor ferroptosis -- but FSP1 acts as a counterweight.

Liver cancer. Hepatocellular carcinoma shows FSP1-dependent ferroptosis resistance, and this has been linked to poor outcomes in some studies. Given that the liver is iron-processing central for the body, the interplay between hepatic iron metabolism and FSP1 activity is an area of ongoing research.

Breast and ovarian cancer. Platinum-resistant ovarian cancer and triple-negative breast cancer both show evidence of ferroptosis evasion involving FSP1, and early cell-line work suggests that FSP1 inhibitors can resensitize these cells to platinum-based and PARP inhibitor regimens.

Important caveat: the majority of this evidence comes from cell lines and mouse models. The jump from a cell dish to a human tumor is not trivial, and none of these findings have yet translated into a clinical practice change. We say this not to dismiss the research -- it is genuinely promising -- but because honesty about the evidence tier is part of how we operate.

Therapeutic strategies researchers are testing

If FSP1 is a brake on ferroptosis that cancer cells use to survive, the obvious question is: can we cut the brake line? Several approaches are being explored.

Direct FSP1 inhibition. iFSP1 is the best-characterized small-molecule FSP1 inhibitor in preclinical use. It does not deplete CoQ10 globally -- it specifically blocks FSP1's oxidoreductase activity, which reduces ubiquinol regeneration at the membrane without systemically disrupting mitochondrial CoQ10 function. Combined with GPX4 inhibitors, iFSP1 produces synergistic ferroptotic cell death in several cancer models (https://pubmed.ncbi.nlm.nih.gov/31634900/).

Combination with existing therapies. Radiotherapy has been shown to induce lipid peroxidation in tumor cells (https://pubmed.ncbi.nlm.nih.gov/32572188/). Pairing radiation with FSP1 inhibition is a logical combination -- radiation raises the oxidative pressure, and FSP1 inhibition removes a key escape valve. Similar rationale applies to certain immunotherapy contexts, where ferroptosis in tumor cells may amplify immune-mediated killing.

Targeting the NADH supply. Because FSP1 depends on NADH, disrupting the NAD+/NADH ratio in tumor cells could theoretically reduce FSP1 activity indirectly. This is a more systemic intervention and carries real risk of off-target effects in healthy tissue. It is early-stage thinking, not a protocol.

Nanoparticle delivery. A parallel thread in cancer therapeutics involves delivering ferroptosis-inducing compounds directly into tumors using lipid or polymer nanoparticles to reduce systemic toxicity -- an approach also being studied for other drugs in glioblastoma models. The principle of localized delivery to spare healthy tissue is sound; the execution remains technically difficult.

What this means for your health -- and what it does not

If you or someone you care about is in active cancer treatment, none of the above translates into something you should ask your oncologist to prescribe tomorrow. There is no FSP1 inhibitor with a phase III trial, no approved drug in this class, and no supplement that reliably modulates the FSP1-CoQ10 axis with demonstrated antitumor effect in humans.

What does matter is this: the emerging picture of ferroptosis biology helps explain why some cancers resist treatment and gives researchers a mechanistic rationale for new drug combinations. That is genuinely useful science, even if the timeline to clinical application is measured in years, not months.

For people focused on long-term health and cellular resilience -- which is most of the patients we work with at NoMi Beach Health -- the broader lesson from ferroptosis research reinforces something we already know from a systematic review of interventions that extend healthspan: oxidative stress management, iron status, and cellular metabolism are not abstract concepts. They are measurable, modifiable, and clinically relevant across a wide range of conditions, not only cancer.

We look at oxidative stress markers, iron panels, and metabolic labs as part of how we think about functional health at baseline. We are not claiming that optimizing those parameters prevents cancer -- the evidence does not support that claim, and we will not make it. But understanding your iron status, your CoQ10 levels, and your overall antioxidant capacity is not irrelevant to long-term health either.

If you are curious about how we approach cellular health, metabolic testing, and the science behind functional wellness, our functional wellness without the woo pillar post is a good place to start.

The honest bottom line

FSP1 is a real, mechanistically validated target. Its role in helping cancer cells escape ferroptosis is well-supported in preclinical models across multiple cancer types. The therapeutic logic -- inhibit FSP1, remove a key escape route, push cancer cells toward ferroptosis -- is coherent and compelling.

The gap between compelling preclinical logic and effective, safe human therapy is also real, and it is wide. Drug development is hard. Most preclinical targets do not survive clinical trials intact. We think you deserve to know both things at once.

What we can say with confidence is that ferroptosis research represents one of the more scientifically grounded areas of cancer biology right now, and that the FSP1 story is moving fast enough to watch closely. If you want to understand how your own cellular health metrics relate to oxidative biology and what we actually look for in a functional medicine workup, that is a conversation we are built for.

---

If you want a rigorous, honest look at how your metabolic and cellular health markers stack up -- not a sales pitch, just the labs and the interpretation -- book a new-patient visit through our functional medicine services page or call us at (786) 744-5152. Dr. Jezwah Harris (NP, JD, MBA, FNP-BC, MEP-C) will review the results with you directly.